PureTech Health plc
PRTCDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Pirfenidone
Idiopathic Pulmonary Fibrosis
LYT-300
Healthy Volunteers
LYT-200
Metastatic Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Pirfenidone | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
LYT-300 | Phase 2 | Healthy Volunteers | - | - |
LYT-200 | Phase 2 | Metastatic Cancer | - | - |
Frequently asked questions
What is in PureTech Health plc's drug pipeline?→
CatalystAlert tracks 3 drug candidates in PureTech Health plc's (PRTC) pipeline across Phase 2. Its lead program is Pirfenidone (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is PureTech Health plc's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for PureTech Health plc (PRTC) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track PRTC biotech catalysts?→
Add PRTC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow PureTech Health plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.